LFM-A13

• Catalog No.: L6920
• CAS Number: 244240-24-2
• M. F.: C11H8Br2N2O2
• M. W.: 360.00142
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
• IUPAC Traditional name: 2-cyano-N-(2,5-dibromophenyl)-3-hydroxybut-2-enamide
• Synonyms: (2Z)-2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide; a-Cyano-b-hydroxy-b-methyl-N-(2,5-dibromophenyl)propenamide; α-Cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide

DATABASE IDS

• MDL Number: MFCD09878279
• CAS Number: 244240-24-2

PROPERTIES

• Empirical Formula (Hill Notation): C11H8Br2N2O2
• Purity: ≥98% (HPLC)
• Apperance: white to tan powder
• Solubility: DMSO: ≥19 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H312-H332
• European Hazard Symbols: Harmful (Xn)
• GHS Precautionary statements: P280
• Risk Statements: 20/21/22
• Safety Statements: 36/37
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases

Description (简体中文)

Biochem/physiol Actions
LFM-A13 is an inhibitor of the nonreceptor tyrosine kinase Bruton′s tyrosine kinase (Btk), a new molecular target for treatment of B-cell lymphoma and autoimmune disorders. LFMA13 inhibited recombinant BTK with an IC50 value of 2.5microM with 100-fold lower inhibitory activity against a number of other protein kinases including JAK1, JAK2, EGFR, IRK, IKK, and CDK1, 2 and 3, as well as several other related kinases